Lubbe Steven J, Escott-Price Valentina, Gibbs J Raphael, Nalls Mike A, Bras Jose, Price T Ryan, Nicolas Aude, Jansen Iris E, Mok Kin Y, Pittman Alan M, Tomkins James E, Lewis Patrick A, Noyce Alastair J, Lesage Suzanne, Sharma Manu, Schiff Elena R, Levine Adam P, Brice Alexis, Gasser Thomas, Hardy John, Heutink Peter, Wood Nicholas W, Singleton Andrew B, Williams Nigel M, Morris Huw R
Department of Clinical Neuroscience, Institute of Neurology, University College London, London, UK.
Department of Psychological Medicine and Neurology, Institute of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University School of Medicine, Cardiff, UK.
Hum Mol Genet. 2016 Dec 15;25(24):5483-5489. doi: 10.1093/hmg/ddw348.
Oligogenic inheritance implies a role for several genetic factors in disease etiology. We studied oligogenic inheritance in Parkinson's (PD) by assessing the potential burden of additional rare variants in established Mendelian genes and/or GBA, in individuals with and without a primary pathogenic genetic cause in two large independent cohorts totaling 7,900 PD cases and 6,166 controls. An excess (≥30%) of cases with a recognised primary genetic cause had ≥1 additional rare variants in Mendelian PD genes, as compared with no known mutation PD cases (17%) and unaffected controls (16%), supporting our hypothesis. Carriers of additional Mendelian gene variants have younger ages at onset (AAO). The effect of additional Mendelian variants in LRRK2 G2019S mutation carriers, of which ATP13A2 variation is particularly common, may account for some of the variation in penetrance. About 10% of No Known Mutation-PD cases harbour a rare GBA variant compared to known pathogenic mutation PD cases (8%) and controls (5%), with carriers having earlier AAOs. Together, the data suggest that the oligogenic inheritance of rare Mendelian variants may be important in patient with a primary pathogenic cause, whereas GBA increases risk across all forms of PD. This study highlights the potential genetic complexity of Mendelian PD. The identification of potential modifying variants provides new insights into disease mechanisms by potentially separating relevant from benign variants and by the interaction between genes in specific pathways. In the future this may be relevant to genetic testing and counselling of patients with PD and their families.
寡基因遗传意味着多种遗传因素在疾病病因中发挥作用。我们通过评估既定孟德尔基因和/或GBA中其他罕见变异的潜在负担,在两个总计7900例帕金森病(PD)病例和6166例对照的大型独立队列中,研究了有和没有原发性致病遗传原因的个体的寡基因遗传情况。与无已知突变的PD病例(17%)和未受影响的对照(16%)相比,有公认原发性遗传原因的病例中,超过30%在孟德尔PD基因中还有≥1个其他罕见变异,这支持了我们的假设。携带其他孟德尔基因变异的患者发病年龄(AAO)更小。LRRK2 G2019S突变携带者中其他孟德尔变异的影响,其中ATP13A2变异尤为常见,可能解释了部分外显率的差异。与已知致病突变的PD病例(8%)和对照(5%)相比,约10%无已知突变的PD病例携带罕见的GBA变异,携带者的AAO更早。总体而言,数据表明罕见孟德尔变异的寡基因遗传在有原发性致病原因的患者中可能很重要,而GBA会增加所有形式PD的风险。这项研究突出了孟德尔PD潜在的遗传复杂性。潜在修饰变异的鉴定通过潜在地区分相关变异和良性变异以及特定途径中基因之间的相互作用,为疾病机制提供了新的见解。未来,这可能与PD患者及其家属的基因检测和咨询相关。